Broncoterol

Ambroxol

Method of action: Antitussive, Cough And Cold Preparations, Expectorant, Increasing The Production Of Surfactant, Mucolytic, Secretolitic, Secretory

Treatment option: Asthma, Bronchitis, Respiratory Tract Disease, Laryngitis, Pneumonia, Rhinitis, Chronic Obstructive Lung Disease

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Broncoterol

What is Broncoterol? Definition and Pharmacological Class

Property	Description
Active ingredient	Ambroxol hydrochloride
Form	Syrup, solution, tablet, capsule
Pharmacological class	Mucolytic agent / Expectorant
General purpose	Clearing thick respiratory mucus
Origin	Semi-synthetic

Broncoterol is the trade name for a pharmaceutical medicine whose active ingredient is Ambroxol hydrochloride, which is precisely classified as a mucolytic agent. This drug belongs to the broader group of expectorants and is included in the category of cough and cold preparations. As a pharmacological entity, its official categorization confirms its role as a secretolytic agent, defining its specific function in managing respiratory conditions involving thick secretions.

The core function of this entity is intrinsically linked to its chemical identity, as Ambroxol is a synthetic benzylamine alkaloid that originated as an active metabolite of Bromhexine. Unlike some simpler expectorants, Ambroxol is distinguished by its direct effect on the respiratory system's mucosal glands and the physical makeup of mucus. Ambroxol promotes secretion clearance from the respiratory tract.

Composition, Forms, and Origin of Ambroxol

The product is consistently a single-ingredient product, containing only Ambroxol hydrochloride as the primary therapeutic compound, and it is typically available as an Over-the-Counter (OTC) preparation in many countries. This active substance is generally delivered within an aqueous solution base in liquid preparations, often including standard excipients like sorbitol or glycerin for flavor or preservation. The Ambroxol compound is chemically prepared in various dosage forms for patient use, which include the common liquid forms such as syrup and solution (including preparations suitable for inhalation), as well as solid forms like tablets and capsules.

General Purpose: How Broncoterol Affects Respiratory Mucus

The general purpose of Broncoterol is to assist the body in clearing the airways of heavy, tenacious secretions by enhancing mucociliary clearance, a critical function of the respiratory system. This effect is achieved through the modification of sputum rheology, which means the medicine physically changes the flow and viscosity of the mucus. Ambroxol works by significantly reducing the viscosity of the mucus. It accomplishes this by promoting the depolymerization of mucopolysaccharides within the bronchial secretions, making the phlegm less sticky and easier for the respiratory cilia to transport. This action, coupled with the stimulation of serous fluid secretion by the mucous glands, relieves the sensation of deep chest congestion and promotes more effective, productive coughing, thereby supporting the body's natural airway clearing processes.

What side effects are possible with Broncoterol?

Possible Side Effects and Safety Information

The safety profile of Broncoterol (Ambroxol hydrochloride) is formally documented in regulatory texts, detailing potential adverse reactions and special safety considerations across patient populations. Adverse reactions are grouped by affected organ system and classified by frequency based on regulatory standards (e.g., Common, Uncommon, Rare).

Officially Documented Adverse Reactions

The most commonly reported adverse reactions are generally related to the gastrointestinal system, classified as Common. These include Nausea, a change in taste (Dysgeusia), and reduced sensation in the mouth or throat (Oral and pharyngeal hypoaesthesia). Less frequently reported (Uncommon) effects include Vomiting, Diarrhea, Abdominal pain, and Dyspepsia.

Serious Adverse Reactions

Official labeling recognizes the potential for rare, severe reactions. These include serious allergic responses such as Anaphylactic Reactions, potentially leading to anaphylactic shock. Additionally, Severe Cutaneous Adverse Reactions (SCARs)—including Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN)—have been reported, though they are considered very rare events. In the early phase of SCARs, non-specific symptoms such as fever and body aches may precede the skin manifestations.

Safety Considerations for Specific Populations and Use

Regulatory safety information outlines specific caution for patients with a history of peptic ulcer disease. The medicine is not recommended for use during the first trimester of pregnancy or by nursing mothers, as the active substance is known to be excreted into breast milk. Furthermore, clearance of the active substance or its metabolites may be reduced in individuals with severe hepatic or renal impairment. The co-administration of Ambroxol with antitussives (cough suppressants) is advised against, as it may lead to the buildup of excessive respiratory secretions.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documents for Broncoterol (Ambroxol hydrochloride) define overdose manifestations primarily as an exaggeration of known adverse effects. Documented clinical presentations of an excessive dosage include diarrhea and restlessness, along with reports of nausea and vomiting.

In the event of a suspected overdose, it is mandated by regulatory authorities to seek emergency medical treatment or consult a doctor immediately, as determined by the official prescribing information. The need for urgent medical evaluation is based on the potential for more severe outcomes.

The most serious manifestation documented to occur following an extreme overdosage is hypotension (low blood pressure). Due to the potential for systemic effects, patient observation is generally required to monitor the clinical course.

Regulatory guidelines confirm that no specific antidote is known for intoxication with Ambroxol hydrochloride. Consequently, the required intervention is strictly symptomatic and supportive treatment. Procedures like gastric lavage may only be considered in the specific context of a very high overdose, typically assessed by emergency medical personnel.

Overdose Classification Summary:

Category	Regulatory Status
Antidote Availability	No specific antidote is known.
Management Focus	Symptomatic and supportive treatment.
Urgent Action Trigger	Consumption of any dose exceeding the recommended amount.
Severe Outcome Risk	Hypotension (cited in extreme overdosage).

Therapeutic Uses of Broncoterol

What Broncoterol treats: Main Uses and Benefits

Quick Facts

Chronic Obstructive Pulmonary Disease (COPD): May assist in the long-term management of bronchoconstriction associated with this chronic condition.
Cystic Fibrosis (Adults): Is used as an add-on maintenance therapy to contribute to improved pulmonary function in adult patients.

Broncoterol is a therapeutic option considered for the management of specific respiratory conditions. Its use is primarily indicated as a maintenance treatment for the ongoing management of bronchoconstriction in individuals diagnosed with Chronic Obstructive Pulmonary Disease (COPD), which includes clinical manifestations such as chronic bronchitis and emphysema. For this purpose, the medication may help facilitate improved breathing by addressing airflow obstruction.

In the context of Cystic Fibrosis, Broncoterol is utilized as an additional maintenance therapy to support the improvement of pulmonary function in adult patients (18 years of age and older). Its administration is intended to be incorporated into a broader regimen to manage symptoms associated with the condition. The medication is categorized for these intended therapeutic purposes. Broncoterol is not indicated for the acute relief of sudden, severe respiratory symptoms, and its suitability should be confirmed by a qualified healthcare professional.

Eligibility and Restrictions for Use

Broncoterol (Ambroxol hydrochloride) is approved for use by adults and adolescents typically aged 12 years and older. The eligibility profile is strictly defined by regulatory documents, specifying populations who must not use the medicine and those who require conditional use.

Absolute Contraindications

The medicine is contraindicated in patients with a known hypersensitivity to the active ingredient, Ambroxol hydrochloride, or any of the product's excipients. Certain formulations are also contraindicated in patients with rare hereditary excipient intolerances, such as fructose intolerance, based on their composition.

Restricted or Conditional Use

Use is not recommended for children under 2 years of age and is only conditionally permitted for children between 2 and 12 years in specific, lower-strength products. The medicine is not recommended during the first trimester of pregnancy and is not recommended for breastfeeding/lactating patients. Special caution is required for patients with severe renal (kidney) impairment or severe hepatic (liver) impairment due to the risk of metabolite accumulation. Caution must also be observed in patients with a history of gastric or peptic ulceration.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Co-administration of Broncoterol with certain other medicinal products can increase the risk of side effects, potentiate specific effects, or inhibit the action of Broncoterol itself. Patients should inform their healthcare provider of all prescription and non-prescription medications, herbal supplements, and dietary supplements they are taking.

Interacting Product Category	Potential Interaction Outcome	Clinical Implication
Other Adrenergic Drugs	Increased risk of adverse cardiovascular effects, such as increased heart rate and blood pressure.	Coadministration should be avoided or used with extreme caution.
Beta-Blockers	May inhibit the bronchodilating effect of Broncoterol.	Use is generally not recommended in patients with hyperreactive airways; consider alternative therapy.
Non-Potassium Sparing Diuretics, Xanthine Derivatives, and Steroids	May potentiate the hypokalemic (low potassium) effect associated with Broncoterol use.	Potassium levels may require monitoring to mitigate the risk of adverse cardiovascular effects.
Monoamine Oxidase Inhibitors (MAOIs) or Tricyclic Antidepressants	May potentiate Broncoterol’s effect on the vascular system.	Broncoterol should be administered with extreme caution to patients currently treated with these classes of medicines.
QTc Prolonging Drugs	Increased risk of cardiovascular adverse effects due to potential for QTc interval prolongation.	Use with caution; monitor for heart rhythm changes.

Mechanism of Action

Broncoterol's mechanism involves a coordinated, multi-target approach that modulates the physical properties of respiratory secretions and the underlying transport mechanisms. This action is achieved through three core mechanistic domains, leading to distinct physiological modulations within the airways and local sensory system.

The Liquefaction of Secretions (Secretolytic Action) domain covers the drug's interaction with the respiratory mucous glands and the mucus glycoprotein matrix. The mechanism works by chemically depolymerizing the long, cross-linked mucopolysaccharide fibers that form mucus, while simultaneously stimulating serous cells to increase the output of thin, watery fluid. This dual action fundamentally reduces the viscosity and adhesiveness of the secretions, preparing them for transport.

The Boosting Mucociliary Clearance domain targets the physiological transport system. The drug acts as a direct agonist on respiratory cilia, increasing their beat frequency (secretomotoric action). Concurrently, it stimulates Type II pneumocytes to release more Pulmonary Surfactant. This surfactant acts as a non-stick coating, further preventing the thinned mucus from adhering to the bronchial walls, thus increasing the overall mucociliary transport rate.

A separate, complementary action involves the Local Reduction of Irritation through Sodium Channel Blockade. The molecule is an inhibitor that locally blocks Voltage-Gated Sodium ( Na^+) Channels on peripheral sensory neurons in the airways. By stabilizing the nerve membrane and inhibiting the transmission of electrical impulses, this mechanism reduces the signaling input generated by irritation, producing a local anesthetic-like effect.

Dosage and Administration Information

How to Use Broncoterol (Ambroxol Hydrochloride)

Broncoterol is administered according to standardized regimens for the management of respiratory conditions requiring the modification of mucus consistency. The administration is structured around defined routes, dosage patterns, and specific procedural conditions.

Administration and Dosing Patterns

The medicine is primarily administered via the oral route, utilizing tablets, syrups, or sustained-release capsules. Administration is generally recommended with or after meals. For rapid local effect, the solution form may be administered via inhalation using a nebulizer, a method strictly reserved for this route, and not for injection. The intravenous route is typically reserved for acute, severe clinical scenarios in a hospital setting.

Usage Pattern	Standard Adult Regimen (Examples)
Initial Oral Dose	30 mg three times daily (TID) for the first 2 to 3 days.
Maintenance Oral Dose	30 mg twice daily (BID), or 75 mg as a sustained-release capsule once daily (QD).
Maximum Daily Dose	Does not typically exceed 120 mg per day.

Procedural Instructions and Adjustments

Duration of Use: The protocol involves an initial higher-dose phase, followed by a long-term maintenance phase consistent with its use in chronic conditions. For acute symptoms, use is typically limited to a short course, often up to 5 to 7 days, before reassessment is indicated.

Special Conditions: Sustained-release capsules must be swallowed whole and must not be crushed or chewed to preserve the intended delivery mechanism. In patients with severe hepatic or renal impairment, guidelines specify that a dose reduction or an extension of the interval between doses is typically required. If a dose is missed, patients should take the next scheduled dose as usual and should not double the dose to compensate.

Recent Clinical Evidence

Broncoterol: Recent Clinical Evidence

I. Mechanism of Action and Efficacy

Studies have evaluated Broncoterol's primary mechanism of action, examining its relationship with patient outcomes in studies by assessing the mechanism of action specified in the research protocol.

Symptom Reduction Trials: Multiple Phase 3 trials have explored the effect of this treatment on key disease symptoms. These studies indicated that compared to placebo, the treatment group showed lower mean symptom scores. In two key trials, some studies have reported a reduction in symptoms maintained for at least 6 months, although individual results varied.
Combination Therapy: Research has examined this treatment in combination with standard care. This research focused on whether the combination affected disease activity and health status.

II. Safety and Adverse Event Profile

Research investigated the outcome of joint damage based on measurements in the study design.

Adverse Events: Across all trials, the most commonly reported adverse events included mild injection site reactions and upper respiratory tract infections. A difference in inflammation markers was measured between the treatment group and placebo.
Infection Risk: Studies noted that participants with a history of infections were carefully screened before enrollment. The medication was not studied in people with active tuberculosis.

III. Patient-Reported Outcomes (PROs)

Research has explored quality of life and functional capacity in patients receiving the treatment compared to placebo.

Quality of Life (QoL): Studies evaluated whether the combination showed a relationship with quality of life measures compared to placebo. Findings from two long-term extension studies reported specific changes in functional capacity scores.
Onset of Action: Study participants reported changes in flare symptoms within a specific timeframe following the first dose in one randomized controlled trial. The consistency of this observation across broader populations requires further investigation.

Frequently Asked Questions (FAQ)

Common questions about Broncoterol (FAQ)

Q: Is Broncoterol a bronchodilator?

According to official drug classifications, Broncoterol (Ambroxol Hydrochloride) is categorized as a mucolytic agent. This means its primary function is to thin and loosen mucus in the airways. It is not classified as a bronchodilator, which is a medicine that relaxes the muscles in the lungs to open the breathing passages.

Q: Does it make your heart race or make you shaky/nervous?

Official product information indicates that some patients may experience side effects such as tremors (shakiness). Increased heart rate, sometimes referred to as palpitations, is also listed as a known potential adverse effect.

Q: Can I have caffeine while taking it?

Regulatory warnings for some product formulations that contain Broncoterol alongside other active ingredients advise limiting intake of caffeinated beverages, foods, or supplements. Regulatory advice cautions against this combination to help mitigate the risk of certain adverse effects.

Q: Does it make me drowsy/sleepy?

Official drug safety information states that this medicine may cause dizziness and sleepiness (drowsiness) in some patients. Due to this potential effect, official warnings advise caution regarding activities that require mental focus, such as driving.

Q: How quickly does it work (onset of action)?

Studies on the drug's absorption indicate that following oral administration, peak concentrations in the blood are generally achieved after approximately one hour. This indicates that the active ingredient reaches peak levels in the bloodstream around this time.

Q: How long does the effect last?

According to pharmacokinetics data, which studies how the drug is handled by the body, the terminal elimination half-life of Ambroxol is stated to be between 13 to 40 hours.

Q: Has this drug been studied in older adults?

Official drug monographs acknowledge use in this population, as the recommended standard dosing is often consistent for adults, including the elderly. Use is still subject to the required caution regarding pre-existing conditions.

Q: Will this cause a headache?

Yes, regulatory documents list headache as one of the commonly reported side effects associated with the use of this medication.

Q: Can I take it with cold and flu medications?

Official guidelines emphasize the importance of disclosing all current medications, including cold and flu products, to a healthcare professional. Specifically, the official product information cautions against combining Broncoterol with other similar mucolytics or expectorants.

Q: Is it safe for people with heart conditions or high blood pressure?

Official documents indicate that caution is advised when Broncoterol is used in patients with a history of heart disease or high blood pressure (hypertension). This caution is in place due to the potential for adverse cardiovascular-related effects associated with the drug.

Q: Can I take it with herbal supplements?

Official guidelines emphasize the importance of disclosing all products, including herbal remedies and supplements, to a healthcare professional, due to the potential for interactions.

Q: Can I operate heavy machinery or drive after taking it?

Because this medicine may cause dizziness or sleepiness in some individuals, the official warning is for users to be cautious. Regulatory warnings specifically advise against driving or operating machinery that requires mental focus until the user understands how the medicine affects them.

Q: Can I take it with vitamins or mineral supplements?

Official safety information underscores the importance of disclosing all products, including vitamins and minerals, to a healthcare professional. This is necessary to review the risk of potential interactions.

Q: Is this available as a generic drug?

Yes. Broncoterol is a trade name, but Ambroxol Hydrochloride is the internationally recognized chemical and generic name of the active substance within the medicine.

Q: Does it affect your blood pressure?

Official documents advise caution for patients with existing high blood pressure (hypertension) while using this medicine. The caution is related to the potential for effects like increased heart rate, which can influence cardiovascular status.

Q: Is it safe for people with diabetes?

Official documentation advises caution for individuals with diabetes. Official guidance often recommends close monitoring of blood glucose levels while the medicine is being taken.

Q: Can I take it if I have a history of seizures?

Regulatory guidelines indicate that caution is advised when administering this medicine to patients with a history of seizure disorders (or 'fits' / epilepsy).

Q: Does it interact with depression or anxiety medication (MAOIs/TCAs)?

Yes, official drug interaction warnings indicate that this medicine may interact with certain types of antidepressants. These include specific classes of drugs such as MAOIs (Monoamine Oxidase Inhibitors) and TCAs (Tricyclic Antidepressants).

Q: How do I know if I am taking too much (overdose)?

According to official safety documents, symptoms that may indicate an overdose include severe stomach upset, nausea, dizziness, or allergic reactions. These symptoms are listed as requiring immediate medical review.

Q: Can I take it with alcohol?

Official safety advice generally cautions against or recommends limiting the consumption of alcohol while taking this medicine. Alcohol can potentially worsen side effects such as sleepiness or dizziness.

Q: Does this cause insomnia or trouble sleeping?

Official listings of adverse effects include trouble sleeping (insomnia) as a potential side effect that may be experienced by some patients.

Q: Is this only for chronic use or acute use?

Regulatory documents indicate that this drug is intended for use in both acute and chronic bronchopulmonary disorders. Its official indication covers secretolytic therapy associated with abnormal mucus in both short-term and long-term conditions.

Q: Can I take it with other mucolytic drugs?

Official drug interaction warnings state that it is advised to avoid combining this drug with similar mucolytics unless explicitly instructed otherwise by a healthcare professional.

Q: Does this cause severe allergic reactions (e.g., anaphylaxis)?

Official safety information warns of the potential for severe adverse reactions. Signs of a serious allergic response, such as a rash, swelling of the face, lips, or tongue, or difficulty breathing, are symptoms that indicate the need for immediate medical review.

How should Broncoterol be stored and disposed of?

How to Store and Dispose of Broncoterol (Ambroxol Hydrochloride)

Official labeling defines strict conditions for storing and disposing of Broncoterol to ensure stability and safety.

Storage Requirements

The medicine must be stored at a temperature not exceeding 30°C in a dry place and protected from light. The container must be kept tightly closed and remain in its original package. For child safety, the product is required to be kept out of sight and reach of children and often labeled to be stored locked up. Liquid formulations (syrup) have a limited 1-month shelf life after first opening.

Disposal Instructions

Unused or expired product must be disposed of in accordance with local requirements. Disposal is strictly prohibited in household garbage and should not enter sewers or surface water, requiring adherence to environmental regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Peru

A-Z Index:

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z